(Q42212470)

18 October 2017

Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®). (English)

1 reference

18 October 2017

1 reference

hepatitis E virus

1 reference

Jun Zhang

9

0 references

author name string

Xiao Zhang

1

1 reference

18 October 2017

Minxi Wei

2

1 reference

18 October 2017

Huirong Pan

3

1 reference

18 October 2017

Zhijie Lin

4

1 reference

18 October 2017

Kaihang Wang

5

1 reference

18 October 2017

Zusen Weng

6

1 reference

18 October 2017

Yibin Zhu

7

1 reference

18 October 2017

Lu Xin

8

1 reference

18 October 2017

Shaowei Li

10

1 reference

18 October 2017

Ningshao Xia

11

1 reference

18 October 2017

Qinjian Zhao

12

1 reference

18 October 2017

language of work or name

English

0 references

publication date

2 June 2014

1 reference

18 October 2017

12

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

18 October 2017

32

1 reference

18 October 2017

32

1 reference

18 October 2017

4039-4050

1 reference

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial

18 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Development of the hepatitis E vaccine: from bench to field.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Virus-like particle-based human vaccines: quality assessment based on structural and functional properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Hepatitis E vaccine development: a 14 year odyssey.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Structural basis for the neutralization and genotype specificity of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Pairwise antibody footprinting using surface plasmon resonance technology to characterize human papillomavirus type 16 virus-like particles with direct anti-HPV antibody immobilization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Characterization of the structural modifications accompanying the loss of HBsAg particle immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Recombinant vaccines for hepatitis E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Safety and efficacy of a recombinant hepatitis E vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Efficient recombinant hepatitis E virus vaccine: mission accomplished?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Maturation of recombinant hepatitis B virus surface antigen particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis E virus structural protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Expression of ORF2 partial gene of hepatitis E virus in tomatoes and immunoactivity of expression products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Dimerization of Hepatitis E Virus Capsid Protein E2s Domain Is Essential for Virus–Host Interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Bioengineering virus-like particles as vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Robustness of iCIEF methodology for the analysis of monoclonal antibodies: an interlaboratory study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Charge heterogeneity of monoclonal antibodies by multiplexed imaged capillary isoelectric focusing immunoassay with chemiluminescence detection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.05.064

10.1016/J.VACCINE.2014.05.064

7 January 2021

Identifiers

DOI

1 reference

18 October 2017

1 reference